Promising role for romiplostim in refractory aplastic anaemia

New data seem to confirm a class effect of TPO‐receptor agonists (TPO‐RA) in the setting of refractory aplastic anaemia. Romiplostim appears to be effective in the same way as as eltrombopag in patients with aplastic anaemia refractory to immunosuppressive therapy, according to a preliminary study. A phase 2/3 open-label trial conducted in Japan and Korea ...

Already a member?

Login to keep reading.

© 2021 the limbic